ASX Announcement

17 November 2026

BELL POTTER HEALTHCARE CONFERENCE 2026

Mach7 Technologies Limited ("Mach7" or the "Company") (ASX: M7T), a healthcare software company providing a broad set of enterprise imaging solutions for modern, AI-enabled healthcare environments, provides the attached presentation which will be delivered by the CEO and Managing Director Teri Thomas at the Bell Potter Healthcare Conference today.

Released on authority of the Board by Teri Thomas, Managing Director and Chief Executive Officer.

For more information, contact:

Investor Relations
Françoise Debelak Dixon
+61 (0) 412 292 977
ir@mach7t.com

About Mach7 Technologies: Mach7 Technologies (ASX: M7T) provides enterprise imaging software that helps healthcare organizations manage, access and share diagnostic imaging data across complex environments. The Mach7 platform includes a Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer and an expanding suite of Flamingo modules, expanding capabilities across workflow, interoperability and data management to support a more complete view of the patient record. Together, these capabilities help healthcare organizations build a unified, longitudinal patient record that integrates diagnostic imaging with broader clinical data. Designed for interoperability and scale, Mach7 is increasingly aligned with leading cloud ecosystems such as Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI), helping customers modernize imaging infrastructure and prepare for AI-enabled clinical workflows. Mach7 serves healthcare organizations worldwide, including integrated delivery networks, national health systems and specialist imaging providers. Visit mach7t.com for more information. Visit mach7t.com for more information.

Forward-looking statements

This announcement may contain forward-looking statements regarding the Company's financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company's management as well as assumptions made by, and information currently available to, the Company's management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.

Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192
Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000
T: +61 1300 384 692
www.mach7t.com

MACH7

Bell Potter Healthcare Conference

From archive to architecture

Mach7 Technologies Limited | ASX: M7T | November 2026

Disclaimer "Forward looking" statements

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited ("M7T") activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) ("Corporation Act")) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

FROM ARCHIVE TO ARCHITECTURE

We complete the patient picture with the patient's pictures.

Imaging data, unified, organised, and secure wherever care happens; and integrated with the Electronic Health Record[1] under the customer's control.



“ From Pixel to Point of Care.”

1. An Electronic Health Record (EHR) is a digital version of a patient’s medical history. It is designed to be comprehensive and securely shared with patients and authorised healthcare providers to support coordinated care. It is broader than the Electronic Medical Record (EMR) but often used interchangeably.

Our steps to growth, in order of speed to revenue

1. Protect and expand the installed base

Existing customer growth is the fastest revenue available to us. We have large blue-chip customers with room for expansion in volumes and products.

2. Win new customers

Targeting well-aligned prospects with products we deliver today, helped by a clear roadmap and supported by a happy customer reference base.

3. Flamingo is easier to adopt

Modules added to the products customers already use, with a lower-cost infrastructure option, and new differentiators to drive new sales. Easier purchasing and deployment due to subscription payments and modularity reduces sales friction.

4. EMR[1] integration and advisory work

Early development paths create more ways to grow the pipeline, get market exposure, and make it easier for customers to buy while also supporting growth in revenue.

1. An Electronic Medical Record (EMR) is a digital patient record, a subset of the EHR.

Increased pace and volume of development on a lower cost base

2.5x
Q1 FY27 capitalised development vs pcp

4.4x
AI-enabled productivity gain

Deeper customer engagement directly drives development.

IMAGING DATA ARCHITECTURE

VNA and Flamingo

One architecture. Flamingo modernises the VNA holding customers' images and adds more capabilities.

ENTERPRISE DIAGNOSTIC VIEWING

eUnity Enterprise Viewer

Modernising and growing the product customers love.

EXECUTION

Improved release process

Faster, fuller, with more customer engagement and communication.





Flamingo

Our innovative next-generation architecture: containerised deployment, a modern, lower-cost database, a unified experience, and new capabilities sold as modules.

Will debut at RSNA (Radiological Society of North America) 2026, the industry's largest imaging meeting, held from 29 Nov to 3 Dec.

- **Foundation**

  A modern core, included as a base to other modules, including expanded DICOM, HL7, FHIR and other APIs.

- **Storage**

  On-premise, cloud and hybrid, with imaging lifecycle management.

- **Worklist**

  A flexible and modern workspace used across complex sites and user types.

- **Sonar**

  Our imaging platform's health: native observability and IT Operations Management (ITOM).

- **Flow**

  Our next evolution in intelligent routing and workflow automation. The right image finds the right place, automatically.

Why customers want Flamingo

Each module saves money, time or risk on the images and systems customers already have installed.

Save money

Buy only what you need

Start with one module and add more later. Customers can buy Flow orchestration without the full VNA, which is how our first new customer started last year.

Save time

One worklist across every site

All types of users can read from a single list in the eUnity viewer they already use, with less switching between systems.

Lower risk and cost

See problems early, on one screen

Sonar builds in monitoring and performance tracking, replacing third-party monitoring tools customers pay for today.

Less manual work

The right image, in the right place

Flow routes images automatically using each customer's rules, so staff spend less time moving studies by hand.

Shaped closely with customers: numerous worklist feedback sessions with early adopters and development partners.



Q1 FY27 SUMMARY

4th consecutive quarter of positive operating cash flow as imaging portfolio advances

1. **Cash generation.** Mach7 delivers four consecutive quarters of positive operating cash flow for the first time in its history.
2. **Receipts of A$7.3M.** Up 58% on pcp[1] reflecting customer growth and continued focus on disciplined cash collection.
3. **Payments of A$7.0M.** 17% lower on pcp demonstrating sustainability of lower cost base following FY26 restructuring.
4. **Revenue quality.** ARR run rate of A$23.5M, up 8.5% in constant currency on pcp due to growth in installed base and new customers going live.
5. **Balance sheet.** A$19.3M cash and no debt supporting continued investment in product innovation and commercial growth.



1. Prior corresponding period (pcp).

A Strategic RSNA

29 November to 3 December · McCormick Place, Chicago · Booth 4116



WHAT RSNA IS

The Radiological Society of North America's annual meeting, the industry's largest global imaging meeting. This year's theme is "At the Center of Care", which harmonises well with “From Pixel to Point of Care”.

OUR PRESENCE

An island booth with a visual overhead draw, four demo stations, a theatre and a private meeting room for closed meetings with customers, prospects, and partners.

WHO ATTENDS

40,000+ attendees from 160 countries, including radiologists, imaging and IT leaders, and health system executives.

WHAT CUSTOMERS WILL SEE

Theatre talks

Short sessions on Flamingo, worklists, AI, eUnity and going live.

Flamingo demonstrated

Hands-on demonstrations of Flamingo modules supplementing the eUnity viewer and VNA.

From reset to growth in the imaging data layer



The reset is largely behind us and we are focused on the growth engine.
The last two phases reflect the company we are building.

LARGELY COMPLETE

Reset and stabilise

A metamorphosis: reset the cost base, protected recurring revenue, transformed leadership and customer support model, and designed the Flamingo architecture. Developed new culture code and AI forward operating model.

NOW

Prove the growth engine

Grow and win customers with today's products. Release new Flamingo products to early adopters. Raise our profile with a new website, branding, outreach and industry expert engagement. Embrace AI and maintain discipline to keep revenue growing faster than costs.

NEXT

Compound and lead

Flamingo modules sold across the base, to net new directly, and through partners, with Sonar monitoring, more image types and more Flamingo modules. Each module a customer adds makes the next easier to buy, sets us apart, and lowers barriers to new sales.

AMBITION

Own the imaging data layer


Imaging is about 90% of healthcare data[1] and most of its growth is outside radiology. As AI uses more of it, from pathology to video triage, it needs one organised, governed source. We intend to be that source.

[1] Towbin, A. (2026, May 21). *Imaging accounts for roughly 90% of healthcare data*. HealthSystemCIO.

Contact Us

Investor Relations, Mach7
Françoise Debelak Dixon
+61 (0) 412 292 977
ir@mach7t.com

Registered Office: Suite 2, Level 11, 385 Bourke St,
Melbourne, VIC 3000



This document was authorised for release to the ASX by Teri Thomas, Managing Director and Chief Executive Officer

Mach7 Technologies Limited